{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:54:30Z","timestamp":1785887670493,"version":"3.56.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Accumulating evidence suggests that tenofovir disoproxil fumarate (TDF) can attenuate liver fibrosis directly, the mechanism of which, however, has not been fully elucidated, and there is a paucity of data concerning whether TDF can also mitigate other chronic liver diseases (CLDs). We aimed to identify the molecular targets and potential mechanism of TDF itself in ameliorating CLDs. RNA-sequencing was performed on mouse liver tissues treated with TDF or normal saline. Then the differentially expressed genes (DEGs) were screened, and enrichment analyses of the function and signaling pathways of DEGs were performed with Database for Annotation, Visualization, and Integrated Discovery (DAVID) and Metascape. Next, protein-protein interaction (PPI) networks were constructed and module analyses were utilized to identify significant genes. Subsequently, the DisGeNET platform was used to identify the potential target genes of TDF in mitigating these diseases. Finally, prediction of the transcription factors (TFs) and microRNAs (miRNAs) of the target genes was done to conjecture the underlying mechanism by which TDF relieved CLDs. As a result, a total of 854 DEGs were identified, and the DEGs were involved mainly in \u201cimmunity,\u201d \u201cinflammation,\u201d and \u201cmetabolism\u201d processes. In addition, 50 significant genes were obtained <jats:italic>via<\/jats:italic> PPI construction and module analyses. Furthermore, by means of DisGeNET, 19 genes (<jats:italic>Adra2a, Cxcl1, Itgam, Cxcl2, Ccr1, Ccl5, Cxcl5, Fabp5, Sell, Lilr4b, Ccr2, Tlr2, Lilrb4a, Tnf, Itgb2, Lgals3, Cxcr4, Sucnr1,<\/jats:italic> and <jats:italic>Mme<\/jats:italic>) were identified to be associated with nine CLDs. Finally, 34 miRNAs (especially mmu-miR-155-5p) and 12\u00a0TFs (especially Nfkb1) were predicted to be upstream of the nine target genes (<jats:italic>Cxcl1, Cxcl2, Ccl5, Ccr2, Sell, Tlr2, Tnf, Cxcr4,<\/jats:italic> and <jats:italic>Mme<\/jats:italic>) of TDF in ameliorating CLDs. In conclusion, our study suggests that TDF have the potential to ameliorate CLDs independently of its antiviral activity by affecting the expression of genes involved in hepatic immune, inflammatory, and metabolic processes <jats:italic>via<\/jats:italic> mmu-miR-155-5p-NF-\u03baB signaling. These findings provided <jats:italic>prima facie<\/jats:italic> evidence for using TDF in CHB patients with concurrent CLDs.<\/jats:p>","DOI":"10.3389\/fmolb.2021.763150","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:31:26Z","timestamp":1637044286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model"],"prefix":"10.3389","volume":"8","author":[{"given":"Yuanqin","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-020-10030-4","article-title":"Abstracts","volume":"14","year":"2020","journal-title":"Hepatol. Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41423-021-00639-2","article-title":"Inflammatory Processes in the Liver: Divergent Roles in Homeostasis and Pathology","volume":"18","author":"Ahmed","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"109398","DOI":"10.1016\/j.cbi.2021.109398","article-title":"Promoted Inhibition of TLR4\/miR-155\/NFkB P65 Signaling by Cannabinoid Receptor 2 Agonist (AM1241), Aborts Inflammation and Progress of Hepatic Fibrosis Induced by Thioacetamide","volume":"336","author":"Ali","year":"2021","journal-title":"Chemico-Biological Interactions"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2105-4-2","article-title":"An Automated Method for Finding Molecular Complexes in Large Protein Interaction Networks","volume":"4","author":"Bader","year":"2003","journal-title":"BMC Bioinformatics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1074\/jbc.M110.145870","article-title":"Up-regulation of MicroRNA-155 in Macrophages Contributes to Increased Tumor Necrosis Factor \u03b1 (TNF\u03b1) Production via Increased mRNA Half-Life in Alcoholic Liver Disease","volume":"286","author":"Bala","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/microorganisms9050968","article-title":"High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities","volume":"9","author":"Bockmann","year":"2021","journal-title":"Microorganisms"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DNA Level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108846","DOI":"10.1016\/j.biopha.2019.108846","article-title":"The Effect and Mechanisms of Fuzheng Huayu Formula against Chronic Liver Diseases","volume":"114","author":"Chen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic Steatohepatitis Is Associated with Liver\u2010Related Outcomes and All\u2010Cause Mortality in Chronic Hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.26277","article-title":"Efficacy of Tenofovir Disoproxil Fumarate at 240 Weeks in Patients with Chronic Hepatitis B with High Baseline Viral Load","volume":"58","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s00330-019-06451-x","article-title":"How Intrahepatic Cholestasis Affects Liver Stiffness in Patients with Chronic Hepatitis B: A Study of 1197 Patients with Liver Biopsy","volume":"30","author":"Guo","year":"2020","journal-title":"Eur. Radiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","article-title":"Trrust V2: An Expanded Reference Database of Human and Mouse Transcriptional Regulatory Interactions","volume":"46","author":"Han","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/1756283X16630712","article-title":"Novel Bile Acid Therapeutics for the Treatment of Chronic Liver Diseases","volume":"9","author":"Hegade","year":"2016","journal-title":"Therap Adv. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the Liver - from Homeostasis to Disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e34198","DOI":"10.1371\/journal.pone.0034198","article-title":"Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis B","volume":"7","author":"Jin","year":"2012","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"D239","DOI":"10.1093\/nar\/gkx1141","article-title":"DIANA-TarBase V8: A Decade-Long Collection of Experimentally Supported miRNA-Gene Interactions","volume":"46","author":"Karagkouni","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: A Fast Spliced Aligner with Low Memory Requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3350\/cmh.2018.0054","article-title":"Influence of Hepatic Steatosis on the Outcomes of Patients with Chronic Hepatitis B Treated with Entecavir and Tenofovir","volume":"25","author":"Kim","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: Accurate Transcript Quantification from RNA-Seq Data with or without a Reference Genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1038\/s41424-018-0007-6","article-title":"Increasing Co-Morbidities in Chronic Hepatitis B Patients: Experience in Primary Care and Referral Practices during 2000-2015","volume":"9","author":"Liu","year":"2018","journal-title":"Clin. Translational Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir Disoproxil Fumarate Reduces Hepatocellular Carcinoma, Decompensation and Death in Chronic Hepatitis B Patients with Cirrhosis","volume":"50","author":"Liu","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of Cirrhosis during Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B: A 5-year Open-Label Follow-Up Study","volume":"381","author":"Marcellin","year":"2013","journal-title":"The Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten\u2010Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B Virus Infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for Chemokines in Liver Disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1091581814565669","article-title":"Tenofovir Disoproxil Fumarate","volume":"34","author":"Ng","year":"2015","journal-title":"Int. J. Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/apt.15867","article-title":"Increasing Comorbidities in a South Korea Insured Population-Based Cohort of Patients with Chronic Hepatitis B","volume":"52","author":"Oh","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2165\/10482940-000000000-00000","article-title":"Tenofovir Disoproxil Fumarate","volume":"69","author":"Perry","year":"2009","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"D845","DOI":"10.1093\/nar\/gkz1021","article-title":"The DisGeNET Knowledge Platform for Disease Genomics: 2019 Update","volume":"48","author":"Pi\u00f1ero","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7150\/ijbs.28422","article-title":"ING4 Suppresses Hepatocellular Carcinoma via a NF-\u03baB\/miR-155\/FOXO3a Signaling Axis","volume":"15","author":"Qian","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose Translation from Animal to Human Studies Revisited","volume":"22","author":"Reagan\u2010Shaw","year":"2008","journal-title":"FASEB j."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic Hepatitis B Virus Infection","volume":"392","author":"Seto","year":"2018","journal-title":"The Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"459A","DOI":"10.1002\/hep.26848","article-title":"Signal Transduction and Cell Function","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-wide Experimental Datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408347.2020.1842172","article-title":"Application of Metabolomics in Diagnosis and Treatment of Chronic Liver Diseases","author":"Tang","year":"2020","journal-title":"Crit. Rev. Anal. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/hep.23100","article-title":"Role of microRNA-155 at Early Stages of Hepatocarcinogenesis Induced by Choline-Deficient and Amino Acid-Defined Diet in C57BL\/6 Mice","volume":"50","author":"Wang","year":"2009","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/bioinformatics\/btp612","article-title":"DEGseq: An R Package for Identifying Differentially Expressed Genes from RNA-Seq Data","volume":"26","author":"Wang","year":"2010","journal-title":"Bioinformatics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1053\/j.gastro.2017.07.001","article-title":"Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men with Chronic Hepatitis B: A Large Cohort Study","volume":"153","author":"Yu","year":"2017","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.intimp.2016.09.011","article-title":"Fine-Tuning the Expression of microRNA-155 Controls Acetaminophen-Induced Liver Inflammation","volume":"40","author":"Yuan","year":"2016","journal-title":"Int. Immunopharmacology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12072-019-09997-6","article-title":"TAF and TDF Attenuate Liver Fibrosis through NS5ATP9, TGF\u03b21\/Smad3, and NF-\u039ab\/nlrp3 Inflammasome Signaling Pathways","volume":"14","author":"Zhao","year":"2020","journal-title":"Hepatol. Int."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.763150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:31:32Z","timestamp":1637044292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.763150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":46,"alternative-id":["10.3389\/fmolb.2021.763150"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.763150","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"article-number":"763150"}}